The ability of prostratin to induce T-cell activation through PKC, without tumor promoting ability, has made prostratin the subject of studies for its possible use as an inductive adjuvant therapy in the context of anti-retroviral therapy (ART) [33]. This evidence concerns the gene PRRT2 and neoplasm.